ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the presentation of data from the Phase II -019 Study of pimavanserin in Alzheimer’s disease psychosis at the 10th Clinical Trials on Alzheimer’s Disease meeting in Boston.
from Dementia Big http://ift.tt/2zxf42d via alcoholic dementia
http://ift.tt/2zyen8S
No comments:
Post a Comment